Stryker has secured FDA clearance for its Incompass total ankle system to treat patients whose ankle joints have been damaged by severe rheumatoid, post-traumatic or degenerative arthritis.
The platform will integrate Stryker’s Inbone and Infinity systems into a single, comprehensive ankle replacement system, according to a June 25 news release.
Incompass incorporates Adaptis Boney Ingrowth Technology and redesigned instrumentation to tackle the toughest challenges in total ankle replacement, such as intraoperative adaptability and procedural efficiency.
The ankle system is informed by data from more than 85,000 CT scans and 100,000 clinical cases, according to the release.
Incompass also features a continuum of implant and instrument options designed to accommodate both surgeon preference and patient anatomy, allowing surgeons greater control across multiple planes, updated implant holders and trial tools for improved handling.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.